[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608549":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":29,"responsibleParty":252,"collaborators":20,"id":254,"slug":255,"hasResults":256,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":20,"eligibilityCriteria":260,"healthyVolunteers":256,"sex":261,"minAge":262,"maxAge":20,"enrollmentInfo":263,"targetDuration":20,"studyType":266,"phases":267,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":46,"whyStopped":20,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MAS825","EXPERIMENTAL","Experimental drug",[13],"Drug: MAS825",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],[19],"Arumakimig",null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":23,"role":24,"phone":28,"phoneExt":20,"email":20},"+41613241111",[30,44,63,80,93,98,108,116,124,132,140,145,156,164,172,183,192,201,211,217,225,233,243],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":20},"Cincinnati Childrens Hospital","ACTIVE_NOT_RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-84.51439,39.12711,{"lat":42,"lon":41},{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":36,"countryCode":37,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Legacy Emanuel Research Hosp Portland","RECRUITING","Portland","Oregon","97232",{"type":39,"coordinates":51},[52,53],-122.67621,45.52345,{"lat":53,"lon":52},[56,60],{"name":57,"role":24,"phone":58,"phoneExt":20,"email":59},"Brenna Bogle","+1 503 413 5447","bbogle@lhs.org",{"name":61,"role":62,"phone":20,"phoneExt":20,"email":20},"Daniel Joseph Kingsbury","PRINCIPAL_INVESTIGATOR",{"facility":64,"status":46,"city":65,"state":66,"zip":67,"country":36,"countryCode":37,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University of Utah","Salt Lake City","Utah","84113",{"type":39,"coordinates":69},[70,71],-111.89105,40.76078,{"lat":71,"lon":70},[74,78],{"name":75,"role":24,"phone":76,"phoneExt":20,"email":77},"Tressie Rollins","+1 415 515 8212","tressie.rollins@hsc.utah.edu",{"name":79,"role":62,"phone":20,"phoneExt":20,"email":20},"Aimee Ogden Hersh",{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":20},"Novartis Investigative Site","WITHDRAWN","Montreal","Quebec","H3T 1C5","Canada","CA",{"type":39,"coordinates":89},[90,91],-73.58781,45.50884,{"lat":91,"lon":90},{"facility":81,"status":82,"city":83,"state":84,"zip":94,"country":86,"countryCode":87,"cosmosGeoPoint":95,"geoPoint":97,"contacts":20},"H4A 3J1",{"type":39,"coordinates":96},[90,91],{"lat":91,"lon":90},{"facility":81,"status":46,"city":99,"state":20,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":20},"Bordeaux","33076","France","FR",{"type":39,"coordinates":104},[105,106],-0.58046,44.84124,{"lat":106,"lon":105},{"facility":81,"status":46,"city":109,"state":20,"zip":110,"country":101,"countryCode":102,"cosmosGeoPoint":111,"geoPoint":115,"contacts":20},"Bron","69677",{"type":39,"coordinates":112},[113,114],4.91303,45.73865,{"lat":114,"lon":113},{"facility":81,"status":46,"city":117,"state":20,"zip":118,"country":101,"countryCode":102,"cosmosGeoPoint":119,"geoPoint":123,"contacts":20},"Le Kremlin-Bicêtre","94275",{"type":39,"coordinates":120},[121,122],2.36073,48.81471,{"lat":122,"lon":121},{"facility":81,"status":46,"city":125,"state":20,"zip":126,"country":101,"countryCode":102,"cosmosGeoPoint":127,"geoPoint":131,"contacts":20},"Lille","59037",{"type":39,"coordinates":128},[129,130],3.05512,50.63391,{"lat":130,"lon":129},{"facility":81,"status":46,"city":133,"state":20,"zip":134,"country":101,"countryCode":102,"cosmosGeoPoint":135,"geoPoint":139,"contacts":20},"Paris","75015",{"type":39,"coordinates":136},[137,138],2.3488,48.85341,{"lat":138,"lon":137},{"facility":81,"status":46,"city":133,"state":20,"zip":141,"country":101,"countryCode":102,"cosmosGeoPoint":142,"geoPoint":144,"contacts":20},"75970",{"type":39,"coordinates":143},[137,138],{"lat":138,"lon":137},{"facility":81,"status":46,"city":146,"state":147,"zip":148,"country":149,"countryCode":150,"cosmosGeoPoint":151,"geoPoint":155,"contacts":20},"Sankt Augustin","North Rhine-Westphalia","53757","Germany","DE",{"type":39,"coordinates":152},[153,154],7.197,50.77538,{"lat":154,"lon":153},{"facility":81,"status":46,"city":157,"state":20,"zip":158,"country":149,"countryCode":150,"cosmosGeoPoint":159,"geoPoint":163,"contacts":20},"Heidelberg","69120",{"type":39,"coordinates":160},[161,162],8.69079,49.40768,{"lat":162,"lon":161},{"facility":81,"status":46,"city":165,"state":20,"zip":166,"country":149,"countryCode":150,"cosmosGeoPoint":167,"geoPoint":171,"contacts":20},"Münster","48149",{"type":39,"coordinates":168},[169,170],7.62571,51.96236,{"lat":170,"lon":169},{"facility":81,"status":46,"city":173,"state":174,"zip":175,"country":176,"countryCode":177,"cosmosGeoPoint":178,"geoPoint":182,"contacts":20},"Florence","FI","50139","Italy","IT",{"type":39,"coordinates":179},[180,181],11.24626,43.77925,{"lat":181,"lon":180},{"facility":81,"status":46,"city":184,"state":185,"zip":186,"country":176,"countryCode":177,"cosmosGeoPoint":187,"geoPoint":191,"contacts":20},"Genova","GE","16147",{"type":39,"coordinates":188},[189,190],11.87211,45.21604,{"lat":190,"lon":189},{"facility":81,"status":46,"city":193,"state":194,"zip":195,"country":176,"countryCode":177,"cosmosGeoPoint":196,"geoPoint":200,"contacts":20},"Roma","RM","00165",{"type":39,"coordinates":197},[198,199],11.10642,44.99364,{"lat":199,"lon":198},{"facility":81,"status":32,"city":202,"state":20,"zip":203,"country":204,"countryCode":205,"cosmosGeoPoint":206,"geoPoint":210,"contacts":20},"Utrecht","3584 CX","Netherlands","NL",{"type":39,"coordinates":207},[208,209],5.12222,52.09083,{"lat":209,"lon":208},{"facility":81,"status":46,"city":212,"state":213,"zip":214,"country":215,"countryCode":216,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"Esplugues","Barcelona","08950","Spain","ES",{"facility":81,"status":46,"city":218,"state":20,"zip":219,"country":215,"countryCode":216,"cosmosGeoPoint":220,"geoPoint":224,"contacts":20},"Madrid","28046",{"type":39,"coordinates":221},[222,223],-3.70256,40.4165,{"lat":223,"lon":222},{"facility":81,"status":46,"city":226,"state":20,"zip":227,"country":215,"countryCode":216,"cosmosGeoPoint":228,"geoPoint":232,"contacts":20},"Valencia","46026",{"type":39,"coordinates":229},[230,231],-0.37966,39.47391,{"lat":231,"lon":230},{"facility":81,"status":46,"city":234,"state":235,"zip":236,"country":237,"countryCode":20,"cosmosGeoPoint":238,"geoPoint":242,"contacts":20},"Istanbul","Fatih","34098","Turkey (Türkiye)",{"type":39,"coordinates":239},[240,241],28.94966,41.01384,{"lat":241,"lon":240},{"facility":81,"status":46,"city":244,"state":245,"zip":246,"country":237,"countryCode":20,"cosmosGeoPoint":247,"geoPoint":251,"contacts":20},"Ankara","Sihhiye-Altindag","06230",{"type":39,"coordinates":248},[249,250],32.85427,39.91987,{"lat":250,"lon":249},{"type":253,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100608549","phase-2-a-phase-ii-trial-to-evaluate-the-clinical-efficacy-safety-and-tolerability-of-mas825-in-pediatric-and-adult-participants-with-stills-disease-100608549",false,"NCT07203001","A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease","An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease","Inclusion Criteria:\n\n* Age ≥ 1 with a diagnosis of Still's Disease\n* Active diseases defined as:\n* CRP or ferritin levels greater than ULN, and any of:\n\n  * Fever ≥ 38°C attributed to Still's Disease activity and documented for a number of days prior to Day 1 or\n  * Rash attributed to Still's Disease activity or\n  * Musculoskeletal involvement: arthritis in a number of joints per ACP criteria for active joint or\n  * Serositis or\n  * Macrophage activation syndrome activity as defined by ferritin levels and at least one of: platelet count, a biomarker or fibrinogen levels attributed to Still's Disease activity by the investigator\n* Intolerance or inadequate response to available biologic therapy\n\nExclusion Criteria:\n\n* Patients out of weight range\n* Ongoing or previous treatment with immunomodulatory drugs\n\n  * A limited number of Still's Disease patients that have previously received MAS825 through a managed access program are permitted on the study\n* Glucocorticoid dose exceeding a set limit\n* Any conditions or significant medical problems which places the patient at unacceptable risk for MAS825 therapy\n\n  * Still's disease patients with evidence of macrophage activation syndrome are permitted in the study\n  * Still's Disease patients with evidence of interstitial lung disease including those requiring supplemental oxygen therapy are permitted in the study\n* History of ongoing, chronic or possibly recurrent infection (e.g. HIV, TB, HCV, HBV) and\u002For symptoms and signs of clinically significant active bacterial, fungal or viral infections\n* Live vaccinations within a set time prior to MAS825 treatment. Live vaccines are prohibited up to several months following the last dose\n* History of malignancy of any organ system, including post-transplant lymphoproliferative disorder, treated or untreated, within a number of years, regardless of whether there is evidence of local recurrence and metastases\n* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes or to any of the excipients\n* Pregnant or breastfeeding women\n* Women of child-bearing potential who do not agree to comply with required contraceptive use\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","1 Year",{"count":264,"type":265},30,"ESTIMATED","INTERVENTIONAL",[268],"PHASE2","The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease",[271],"Still´s Disease",[273,274,275,276,277,278,279,280,9,281],"Still´s disease","pediatric","adult","sJIA","AOSD","Systemic Juvenile Idiopathic Arthritis","Adult Onset Still s disease","rheumatology","arumakimig","2026-08-18",{"date":284,"type":285},"2026-08-19","ACTUAL",{"date":287,"type":285},"2025-11-03",{"date":289,"type":265},"2028-05-17",{"name":23,"class":6},23]